MedTrace Logo

Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure

NCT05540834 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-04-17

No results posted yet for this study

Summary

Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.

Conditions

  • Acute Respiratory Failure
  • Hypercoagulability
  • Fibrinolysis Shutdown

Interventions

DRUG

Alteplase

The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.

Sponsors & Collaborators

  • South West Sydney Local Health District

    lead OTHER

Principal Investigators

  • Anders Aneman · Sydney WAHS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2026-05-01
Completion
2026-12-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05540834 on ClinicalTrials.gov